Compare Caesars Entertainment Inc (CZR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Caesars Entertainment Inc vs TG Therapeutics Inc — how do they compare? Caesars Entertainment Inc trades at $29.5 (market cap $6.02B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Caesars Entertainment Inc is more actively traded (6,412,151 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold Caesars Entertainment Inc for 31 Days and TG Therapeutics Inc for 16 Days on average.
| CZR | TGTX | |
|---|---|---|
Market Cap | $6.02B | $8.16B |
Volume | 6,412,151 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $30.41 | $59.06 |
52-Week Low | $18.14 | $26.94 |
Typical Hold Time | 31 Days | 16 Days |
Enterprise Value | $29.91B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CZR trades at $29.52, up 0.1% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $502 million in 2025, with negative profit margins and consecutive earnings misses. A pending merger with Fertitta Entertainment at $31 per share is under regulatory review, while analyst consensus is mixed with a $30.75 price target.
The outlook is cautious due to persistent losses and high debt, though cash flow from operations remains positive. Risks include merger uncertainty and competitive pressures, but the stock trades below some valuation metrics, offering potential upside if profitability improves post-merger.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
